Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Pros: Easy to remember
Monitoring plan : Establish a clear schedule for: Blood glucose monitoring (frequency and target ranges) HbA1c testing (typically every 36 months) Kidney function tests (eGFR and urine albumin-to-creatinine ratio) Blood pressure checks Weight monitoring Follow-up appointments Practical considerations : Injection technique for Wegovy (administered once weekly subcutaneously) Timing of Jardiance (usually once daily in the morning) Managing side effects, particularly gastrointestinal symptoms from Wegovy Sick day rulesspecifically when to temporarily stop Jardiance (during acute illness, dehydration, or 3 days before surgery) When and how to monitor ketones if unwell Contraception planning if applicable Cost implications and prescription arrangements When to seek urgent medical attention : Ensure you understand warning signs requiring immediate healthcare contact, including symptoms of DKA, severe dehydration, Fournier's gangrene, pancreatitis, or unexplained illness
Instead, Wegovy and other medications are approved for weight loss, offering the support you need and possibly securing better insurance coverage
Rababah AM, Matani BR, Yehya A
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
US$ 25.65
US$ 26.12
US$ 24.15
US$ 20.45
